Edwards TAVR segment reached $1.1bn in Q2 2025, up 8.9% compared to Q2 2024, while its heart valve segment increased by 61.9% ...

Edwards Lifesciences stock surged late Thursday after the medtech hiked its outlook following a key setback for rival Boston ...

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2025. Recent Highlights. Q2 sales g ...

Transcatheter aortic valve replacement (TAVR) with the contemporary Sapien 3 device generally held up against surgery in intermediate-risk patients over 5 years, according to a propensity-matched ...

JenaValve announced today that it began patient enrollment in the ARTIST study evaluating its Trilogy TAVR system.

Meeting Coverage > TCT Could Sapien Valve Weather 25 Years With Little Wear? — A billion beats in bench testing say yes. by Crystal Phend, Senior Associate Editor, MedPage Today September 26, 2019 ...

About 300,000 U.S. patients suffer from deterioration of the aortic heart valve, which forces the heart to work harder to pump blood, often leading to heart failure, blood clots and sudden death.

Pitted against more established balloon-expandable Sapien 3 valves in TAVR for severe aortic stenosis, the Myval devices (Myval or Myval Octacor) were able to meet noninferiority with respect to ...

SAN FRANCISCO, CA-- Edwards Lifesciences Corporation, the global leader in the science of heart valves and hemodynamic monitoring, announced that preliminary results from The PARTNER II Trial ...

The balloon-expandable Sapien 3 series, which includes the next-generation Sapien 3 Ultra, is the first transcatheter heart valve to receive CE Mark approval for use in the low-risk setting. The ...

Contacts. Media Contact: Howard Wright, 949-250-2790 Investor Contact: Mark Wilterding, 949-250-6826 ...